** Shares of drugmaker ImmunityBio IBRX.O rise 4.4% to $2.35

** Co says early data shows its experimental cancer treatment regimen shows promise when tested in five patients

** Co was testing its treatment regimen in patients with recurrent glioblastoma or brain tumor

** Co says all five patients achieved 100% disease control with the treatment regimen which also includes its drug Anktiva which is approved to treat a type of bladder cancer

** Including session's move, stock down 12.1% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))